Updates

Announcements

Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild

Mar 10, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled “Accelerated Bookbuild for the Issue of Equity”, the accelerated Bookbuild, which was oversubscribed, has now closed. The Company has raised a total of £4.1 million (before expenses) by way of an issue…
Accelerated Bookbuild for the Issue of Equity

Mar 10, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a proposed placing, raising a minimum of £3 million (before expenses), via the issue of new ordinary shares of 10p each (“Ordinary Shares”) to new and existing investors (the “New Share Placing”). The New Share Placing will provide ImmuPharma with additional…
Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment

Jan 25, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide further details of patient …
Change of Adviser

Jan 24, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect.
Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed

Dec 22, 2016

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that patient recruitment has successfully been completed, on target, within the Company’s pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Commenting on this announcement, Tim McCarthy, Chairman…
Update on Cancer Compound IPP-204106 ‘Nucant’

Nov 16, 2016

Mechanism of Action Published in Prestigious Medical Journal ‘Cancer Research’ ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company, is pleased to announce that Cancer Research, the prestigious medical journal of the American Association for Cancer Research (“AACR”), has published a fundamental scientific paper disclosing the mechanism…
Notification of Major Interest by Legal & General

Nov 9, 2016

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,285,714 million Ordinary Shares in the capital of the Company, representing 3.43% of ImmuPharma’s total voting rights. Commenting, Tim McCarthy, Chairman of…
TR1 Notification of Major Interest

Oct 26, 2016

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP (“Lanstead”). Lanstead’s holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%. For full disclosure of the TR1 click here
Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity

Oct 21, 2016

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a proposed placing of 7,100,000 existing ordinary shares of 10p each (“Ordinary Shares”) held by Lanstead Capital L.P. (“Lanstead”) to new institutional investors (the “Vendor Placing”). The Company also announces a proposed placing of up to approximately £0.8 million (before expenses)…
Close of Accelerated Bookbuild

Oct 21, 2016

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled “Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity”, the accelerated bookbuild (the “Bookbuild”) process has now successfully closed. The Company has placed 7,100,000 existing ordinary shares of 10p each (“Ordinary…
INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016

Sep 30, 2016

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2016 (the “Period”). Key Highlights (including post Period review) Lupuzor™: is the Company’s lead programme for the potential breakthrough compound for Lupus a potential life threatening auto-immune…
Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting

Sep 14, 2016

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Key Trial Highlights Total 11 sites now active in US 5 European…
ImmuPharma Invited to Open an Additional Site in Mauritius

Sep 7, 2016

Up to 30 Lupus patients ready for enrolment ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. ImmuPharma has been requested…
ImmuPharma Invited to Open an Additional Site in Mauritius

Sep 7, 2016

Up to 30 Lupus patients ready for enrolment ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. ImmuPharma has been requested…
Northland Capital Appointed as Joint Broker

Jun 20, 2016

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces the appointment of Northland Capital Partners as joint broker to the Company, alongside Panmure Gordon with immediate effect.
Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller

Jun 8, 2016

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor™, the Company’s lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial. This event, to…
First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

Jun 7, 2016

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the first European sites opened…
Notification of Major Interest by Alto Invest to 4.15%

May 31, 2016

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 30 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming that it has increased its holding to 5,053,548 million Ordinary Shares in the capital of the Company. This represents 4.15% of ImmuPharma’s total voting…
Notification of Major Interest by Alto Invest

May 25, 2016

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 24 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming its holding in ImmuPharma of 4,870,367 million Ordinary Shares in the capital of the Company, representing 3.99% of the Company’s total voting rights, crossing…
PRELIMINARY RESULTS  for the year ended 31 December 2015

May 4, 2016

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary results for the year ended 31 December 2015. Key Highlights: Lupuzor™ Pivotal Phase III clinical trial for Lupuzor™, the Company’s lead programme for the potential breakthrough compound for Lupus, is progressing, in conjunction with Simbec-Orion,…
Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016

May 4, 2016

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2015 has been posted to shareholders. The 2015 Annual Report can be downloaded here The Company’s Annual General Meeting will be held on Thursday 26 May 2016 at…

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2011 (2)

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild

Accelerated Bookbuild for the Issue of Equity

Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment

Change of Adviser

Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed

Update on Cancer Compound IPP-204106 ‘Nucant’

Notification of Major Interest by Legal & General

TR1 Notification of Major Interest

Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity

Close of Accelerated Bookbuild

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016

Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting

ImmuPharma Invited to Open an Additional Site in Mauritius

ImmuPharma Invited to Open an Additional Site in Mauritius

Northland Capital Appointed as Joint Broker

Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller

First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

Notification of Major Interest by Alto Invest to 4.15%

Notification of Major Interest by Alto Invest

PRELIMINARY RESULTS  for the year ended 31 December 2015

Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016